FLORENCE, Italy -- April 5, 2017 -- Individuals treated with angiotensin II receptor blockers (ARBs), including losartan, valsartan, and candesartan, experience a decreased risk for age-related cognitive decline and dementia, according to results of a cross-sectional analysis presented at the 25th European Congress of Psychiatry (EPA).
Lead author Dominik Wincewicz, MD, Medical University of Bialystok, Bialystok, Poland and colleagues observed a significant decrease in the risk for cognitive decline in subjects who received ARB treatment over the course of approximately 9 years of follow up (odds ratio [OR] = 0.445, 95% confidence interval [CI] = 0.22 to 0.90, P = .024). The risk of dementia also was decreased significantly in participants treated with ARBs (hazard ratio [HR] = 0.621, 95% CI = 0.40 to 0.98, P = .038), added Dr. Wincewicz, speaking here on April 2.
He and his fellow investigators analysed data from the population-based, longitudinal Kuopio Ischemic Heart Disease (KIHD) Risk Factor Study, an extensive epidemiologic research project launched in the 1980s, which initially involved nearly 3,000 middle-aged men from the Kuopio region in Eastern Finland. A decade later, over 1,000 women of the same age were recruited to the study. A major part of the original cohorts have been re-examined 4, 11, and 20 years after the baseline.
The researchers included a total of 1,774 subjects (920 females; baseline age range: 42 to 61 years). They utilised a cut-off score of ≥ 2 point decrease in the Mini-Mental-State Examination over a 9-year follow-up period to detect age-related cognitive decline, and a hospital discharge diagnosis of dementia as the outcome variable for dementia.
Using logistic regression, the investigators determined cross-sectional relationships, and conducted prospective analyses with the Cox proportional hazards model. The team adjusted analyses for all relevant background variables.
ARBs modulate the brain renin-angiotensin system (RAS), and have been shown to improve cognitive functioning in animal models of neuropsychiatric disorders. The brain RAS also has been considered as a new target for the treatment of Alzheimer’s Disease.
[Preserved Cognition and Reduced Age Related Cognitive Decline During Treatment with Angiotensin II Receptor Blockers: a 20-year Follow-up Study. Abstract ED773]